A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

A Randomized Multicenter Phase 2 Study Of Dsp-7888 Dosing Emulsion In Combination With Bevacizumab Versus Bevacizumab Alone In Patients With Recurrent Or Progressive Glioblastoma Following Initial Therapy

Brief Description Of Study

The BBI-DSP-7888-201G trial is designed to compare the overall survival (OS) between treatment with DSP-7888 Dosing Emulsion plus bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following initial therapy. This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study. Approximately 200 patients will be enrolled from up to 70 investigational sites in the US, Canada, Japan, Taiwan, and South Korea.

Additional Information About The Study

For more details please visit iConnect and/or email us at NCRD-BTC@uphs.upenn.edu

Clinical Study Identifier: 02498665

Contact research investigator to learn more about this study by filling out the form below.

Your Email:

Not a valid e-mail address

Please Provide Email Address

Your Name:

First name is mandatory

Your Phone Number:

Please provide phone number

Invalid phone number

Valid phone number

Send copy of this to me

To:	Research Study Investigator
Subject:	I am interested in participating in your Research Study
Dear Investigator, I'm interested in learning more about and participating in your research study named: A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.